PL2953973T3 - Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania - Google Patents
Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowaniaInfo
- Publication number
- PL2953973T3 PL2953973T3 PL14703337T PL14703337T PL2953973T3 PL 2953973 T3 PL2953973 T3 PL 2953973T3 PL 14703337 T PL14703337 T PL 14703337T PL 14703337 T PL14703337 T PL 14703337T PL 2953973 T3 PL2953973 T3 PL 2953973T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor binding
- binding agents
- acetylcholine receptor
- muscarinic acetylcholine
- muscarinic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361761136P | 2013-02-05 | 2013-02-05 | |
| US201361961058P | 2013-10-03 | 2013-10-03 | |
| PCT/EP2014/052265 WO2014122183A1 (en) | 2013-02-05 | 2014-02-05 | Muscarinic acetylcholine receptor binding agents and uses thereof |
| EP14703337.7A EP2953973B1 (en) | 2013-02-05 | 2014-02-05 | Muscarinic acetylcholine receptor binding agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2953973T3 true PL2953973T3 (pl) | 2020-01-31 |
Family
ID=50070546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14703337T PL2953973T3 (pl) | 2013-02-05 | 2014-02-05 | Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20150368339A1 (pl) |
| EP (2) | EP3590578A1 (pl) |
| JP (2) | JP2016512954A (pl) |
| AU (1) | AU2014214054B2 (pl) |
| CA (1) | CA2900147C (pl) |
| DK (1) | DK2953973T3 (pl) |
| ES (1) | ES2745772T3 (pl) |
| PL (1) | PL2953973T3 (pl) |
| PT (1) | PT2953973T (pl) |
| WO (1) | WO2014122183A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
| US11466088B2 (en) * | 2017-01-05 | 2022-10-11 | Helix Biopharma Corp. | VEGFR-2 car immune cells to treat cancers |
| CN110382540A (zh) * | 2017-01-05 | 2019-10-25 | 赫利克斯生物药品公司 | Vegfr-2抗体 |
| WO2019032661A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| US11873347B2 (en) | 2017-10-31 | 2024-01-16 | Vib Vzw | Antigen-binding chimeric proteins and methods and uses thereof |
| SG11202111830UA (en) | 2019-04-29 | 2021-11-29 | Confo Therapeutics N V | Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1087013T3 (da) | 1992-08-21 | 2009-05-11 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
| EP1051493A2 (en) | 1998-01-26 | 2000-11-15 | Unilever Plc | Method for producing antibody fragments |
| WO2000040968A1 (en) | 1999-01-05 | 2000-07-13 | Unilever Plc | Binding of antibody fragments to solid supports |
| AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
| WO2000065057A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| US7358096B1 (en) | 1999-11-29 | 2008-04-15 | Conopco, Inc. | Immobilisation of proteins |
| ES2331051T3 (es) | 1999-11-29 | 2009-12-21 | Bac Ip B.V. | Inmovilizacion de moleculas de union de antigenos de un dominio. |
| DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| DK1360207T3 (da) | 2000-12-13 | 2011-09-05 | Bac Ip B V | Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| CA2471116A1 (en) | 2001-12-21 | 2003-07-03 | Serge Muyldermans | Method for cloning of variable domain sequences |
| JP2005517674A (ja) | 2002-01-03 | 2005-06-16 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 腫瘍の処置に有用な新規免疫コンジュゲート |
| WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
| EP2267032A3 (en) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| CN101412759A (zh) | 2003-01-10 | 2009-04-22 | 埃博灵克斯股份有限公司 | 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用 |
| DK1687338T3 (da) | 2003-11-07 | 2011-02-07 | Ablynx Nv | Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf |
| AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
| PL3415535T3 (pl) | 2005-05-20 | 2021-06-14 | Ablynx N.V. | Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP2121757A2 (en) | 2007-02-21 | 2009-11-25 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| AU2009326075B2 (en) | 2008-12-08 | 2014-06-05 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| US9260508B2 (en) | 2008-12-19 | 2016-02-16 | Ablynx N.V. | Method for generation of immunoglobulin sequences |
| WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| WO2012030735A1 (en) | 2010-08-30 | 2012-03-08 | Confometrx, Inc. | Method and composition for crystallizing a family c gpcr |
| WO2012148586A1 (en) | 2011-03-15 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Gpcr fusion protein containing an n-terminal autonomously folding stable domain, and crystals of the same |
| EP2707395B1 (en) | 2011-05-13 | 2017-04-12 | Receptos, Inc. | Novel fusion partners for the purpose of crystallizing g-protein coupled receptors |
| DK2951201T3 (en) * | 2013-01-30 | 2018-01-08 | Vib Vzw | Novel chimeric polypeptides for screening and drug detection purposes |
-
2014
- 2014-02-05 AU AU2014214054A patent/AU2014214054B2/en active Active
- 2014-02-05 PL PL14703337T patent/PL2953973T3/pl unknown
- 2014-02-05 DK DK14703337.7T patent/DK2953973T3/da active
- 2014-02-05 PT PT147033377T patent/PT2953973T/pt unknown
- 2014-02-05 EP EP19184955.3A patent/EP3590578A1/en active Pending
- 2014-02-05 WO PCT/EP2014/052265 patent/WO2014122183A1/en active Application Filing
- 2014-02-05 EP EP14703337.7A patent/EP2953973B1/en active Active
- 2014-02-05 CA CA2900147A patent/CA2900147C/en active Active
- 2014-02-05 JP JP2015555753A patent/JP2016512954A/ja active Pending
- 2014-02-05 US US14/765,824 patent/US20150368339A1/en not_active Abandoned
- 2014-02-05 ES ES14703337T patent/ES2745772T3/es active Active
-
2018
- 2018-03-29 US US15/939,748 patent/US20180222978A1/en not_active Abandoned
-
2019
- 2019-02-22 JP JP2019030146A patent/JP6827485B2/ja active Active
-
2021
- 2021-07-02 US US17/366,755 patent/US20210340249A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2900147C (en) | 2023-09-05 |
| AU2014214054A1 (en) | 2015-08-20 |
| JP2019122378A (ja) | 2019-07-25 |
| WO2014122183A9 (en) | 2016-05-26 |
| EP2953973B1 (en) | 2019-07-10 |
| JP6827485B2 (ja) | 2021-02-10 |
| EP2953973A1 (en) | 2015-12-16 |
| US20150368339A1 (en) | 2015-12-24 |
| ES2745772T3 (es) | 2020-03-03 |
| US20180222978A1 (en) | 2018-08-09 |
| WO2014122183A1 (en) | 2014-08-14 |
| EP3590578A1 (en) | 2020-01-08 |
| US20210340249A1 (en) | 2021-11-04 |
| PT2953973T (pt) | 2019-10-25 |
| JP2016512954A (ja) | 2016-05-12 |
| AU2014214054B2 (en) | 2018-10-04 |
| DK2953973T3 (da) | 2019-08-12 |
| CA2900147A1 (en) | 2014-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225742A1 (zh) | TGF-β受體II型變體及其用途 | |
| HK1219658A1 (zh) | 吡咯並苯並二氮雜卓及其結合物 | |
| HK1219651A1 (zh) | 吡咯並苯並二氮雜卓以及其結合物 | |
| HK1208038A1 (en) | Anti-lgr5 antibodies and immunoconjugates lgr5 | |
| HK1214282A1 (zh) | 抗- 抗體及抗體-藥物綴合物 | |
| HK1214140A1 (zh) | 吡咯並苯並二氮雜卓和其結合物 | |
| HK1208687A1 (en) | Rspo3 binding agents and uses thereof rspo3 | |
| IL234719A0 (en) | Anti-pmel17 antibodies and immunoconjugates | |
| HK1210947A1 (en) | Anticholinergic neuroprotective composition and methods | |
| SI2958944T1 (sl) | Konjugati protiDLL3-protitelo-PBD in njihove uporabe | |
| EP2879708A4 (en) | ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES | |
| IL239643A0 (en) | Converted morphines and their use | |
| GB201317982D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| GB201317981D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| EP2829480A4 (en) | FEEDING AND COUNTERING DEVICE FOR MEDICINAL PRODUCTS | |
| EP2885318A4 (en) | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | |
| EP2888229A4 (en) | ACETYLCHOLINE NICOTINIC A7 RECEPTOR MODULATORS AND USES THEREOF | |
| PT2953973T (pt) | Agentes de ligação do receptor muscarínico de acetilololina e usos | |
| GB2513444B (en) | Improved stopper device | |
| SG11201509448WA (en) | Creamer compositions and uses thereof | |
| EP2968554A4 (en) | MET BINDER AND USES THEREOF | |
| GB201318151D0 (en) | Composition and device | |
| EP2989089A4 (en) | ACETYLCHOLINE ALPHA7 NICOTINIC RECEPTOR MODULATORS AND USES THEREOF | |
| EP2879711A4 (en) | ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES | |
| GB201210989D0 (en) | Composition and device |